Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143520 · ClinicalTrials.gov registry record · Phase 2
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 441
- Enrollment target
NCT00143520: Completed Phase 2 study, sponsored by Daiichi Sankyo.
NCT00143520 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 441 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (232% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00143520, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 441 participants
- Enrollment target
Study Summary
This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic agents. The study tests rivoglitazone and uses a placebo and active treatment group for comparison.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG Rivoglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 441 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00143520 record still lists
NCT00143520 is an interventional study that assigns participants to a tested intervention. The registered 441 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (232% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00143520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00143520 about?
NCT00143520 is a clinical study titled "Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes". This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic agents. The study tests rivoglitazone and uses a placebo and active treatment...
What is the current status of trial NCT00143520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 441 participants. The study started on 2004-12. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00143520?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Rivoglitazone (DRUG).
Who is sponsoring clinical trial NCT00143520?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00143520's enrollment target sits among peer trials
441 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02679144 · 441 participants · Phase 2
Neuroblastoma Maintenance Therapy Trial
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
- NCT04657068 · 442 participants · Phase 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- NCT05410145 · 442 participants · Phase 1
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia